Great Bay Bio 大湾生物’s Post

Introducing the OmniCHO™ Transient Expression Kit, designed to revolutionize preclinical drug development by delivering scalable, high-yield protein production. With yields of over 1 g/L within 5 days or 2g/L in 10-12 days and a cost reduction of up to 30-fold per mg compared to traditional kits, OmniCHO empowers rapid, cost-efficient therapeutic development. Ideal for producing antibodies and hard-to-express proteins, this platform offers a game-changing solution for accelerating research timelines and time to IND. Explore the future of CHO-based expression with Celltheon!" https://lnkd.in/gnvY39Q2 #OmniCHO #Bioprocessing #Celltheon #ProteinProduction #BiotechInnovation

🔬 Keynote Presentation: Hydrophilic Click Chemistry to Widen the Therapeutic Window of ADCs 📅 18 Nov 2024 | 08:30 - 09:00 📍 Antibody Therapeutics Xchange - Brussels - 2024 🔗 Secure your spot today – register now! https://lnkd.in/eqyix7xs In this session, Paul Sauter, Director of Chemistry & Bioconjugation at VERAXA Biotech GmbH will introduce their glycan-engineering based bioconjugation platform. This technology, utilizing hydrophilic click chemistry, has significantly widened the therapeutic window for VERAXA’s anti-HER2 ADCs compared to Enhertu by reducing off-target toxicity. 🌟 Key topics include: 🟡Tackling off-target toxicity in ADCs 🟡VERAXA's bioorthogonal click chemistry platform 🟡In vivo results showing an enhanced safety profile and wider therapeutic window 💡 Learn how VERAXA Biotech GmbH is pushing the boundaries of ADC technology to bring safer, more effective treatments to patients! Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #ADCTherapeutics #AntibodyDrugConjugates #Bioconjugation #PharmaInnovation #Oncology #Veraxa #Therapeutics #HydrophilicClickChemistry #ADCInnovation #CancerTherapeutics #BiotechAdvances #TargetedTherapies #PharmaceuticalResearch #ClinicalDevelopment #OncologyBreakthroughs #DrugDiscovery #BioorthogonalChemistry #NextGenADCs #BioconjugationTechnology #AntibodyEngineering #PharmaR&D #TherapeuticWindow #PrecisionMedicine #Biopharma #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

In 2024, SciLifeLab Drug Discovery & Development needs to replenish its portfolio, of about 20 support programs, with 3-5 new programs. They are looking for: - Programs with defined targets for diseases with medical needs. - Therapeutic ideas based on technologies that can be extended to other targets and/or other indications are of special interest, i.e., therapeutic platform technologies. - Projects to develop therapeutic molecules with innovative mode-of-actions, e.g., targeted delivery or new modes-of-action for antisense oligonucleotides, small molecules, antibodies, and/or proximity-inducers The platform can also consider small projects for selections in phage display libraries for antibodies, selections in DNA-encoded chemical libraries for small molecules, or limited screening for antisense or siRNA oligonucleotides. Read more and apply at: https://lnkd.in/d3-j8cjM

🌟 Innovating the Future of Antibody Therapeutics at the Xchange 2025 🌟 📢 Welcome to hubXchange's Antibody Therapeutics Xchange - San Diego 2025! This premier event gathers senior-level scientists and executives from the pharmaceutical and biotech sectors to address pressing challenges in Antibody Drug Conjugates, Lead Identification & Optimization, Formats & Scaffolds, and Bi/Multispecifics. 💡 Meet Max Cherf 🎯 Director of Mammalian Display at Tentarix Biotherapeutics, Max Cherf has played a pivotal role in advancing biologics. From working along with many scientists and engineers on developing the groundbreaking Transport Vehicle (TV) platform at Denali Therapeutics to driving multi-specifics innovation at Tentarix, Max is at the forefront of biologics discovery and development. 🔍 Spotlight on His Roundtable Max will lead an engaging discussion on developing therapies to target multiple immune pathways, sharing strategies to design effective, multi-pathway therapeutics while minimizing off-target effects. 📅 Event Details 🗓 When: February 19, 2025 📍 Where: Handlery Hotel San Diego 🔗 Register today for only $150! https://lnkd.in/eN74-NS9 🤝 Why Attend? ✔️ Participate in expert-led roundtable discussions. ✔️ Connect in 1:1 meetings tailored to your interests. ✔️ Collaborate with industry leaders in a unique interactive format. 💊 Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #AntibodyTherapeutics #Biologics #Innovation #MultiSpecifics #AntibodyDrugConjugates #Pharma #Biotech #Therapeutics #ClinicalDevelopment #DrugDiscovery #AntibodyEngineering #Biopharma #LifeSciences #TherapeuticDevelopment #ScientificInnovation #ProteinEngineering #hubXchange #Xchanges #Roundtable #RegisterNow

Our update this morning, covered at Benzinga - Enveric Biosciences, Inc. Advances #NonHallucinogenic DMT Analog Drug With Promising Preclinical Results https://lnkd.in/e_YAn2eB

Join us December 10-12 at the 7th Annual RNA-Targeted Drug Discovery & Development Summit in our home city of Boston! We can't wait to explore the latest and greatest in RNA-targeting therapeutics with experts and innovators from across the RNA world.      If that includes you, we'd love to connect and discuss how the Momentum team can accelerate your drug discovery and development project. We have experience working with RNA targets across a wide range of analytical services and can provide customized assay solutions to best tackle your specific research challenges.      On Wednesday, December 11th at 2:30PM, our CEO & Founder Can Ozbal will present "A Complete Workflow for the Identification and Characterization of Small Molecule Modulators of RNA." This talk will describe an end-to-end strategy that can be used to discover, validate, and characterize potent and specific RNA-targeting small-molecule drugs, including covalent drugs.      To schedule a time to meet with the Momentum team at the 7th Annual RNA-Targeted Drug Discovery & Development Summit, send us a message at: https://lnkd.in/dSD6dHDZ     Or, to learn more about the conference, visit: https://lnkd.in/gzcGvHH     #RNADrugDIscovery #RNAResearch #RNA   

I would like to take this opportunity to share that we are introducing the OmniCHO™ Transient Expression Kit, designed to revolutionize preclinical drug development by delivering scalable, high-yield protein production. With yields of over 1 g/L within 5 days and 2-3 g/L within 12 days and a cost reduction of up to 30-fold per mg compared to traditional kits, OmniCHO empowers rapid, cost-efficient therapeutic development. Ideal for producing antibodies and hard-to-express proteins, this platform offers a game-changing solution for accelerating research timelines and time to IND. Explore the future of CHO-based expression with Celltheon!" #OmniCHO #Bioprocessing #Celltheon #ProteinProduction #BiotechInnovation Link to post: Business Wire https://lnkd.in/gQc7-K6R

EXPENSIVE THINGS IN DRUG DISCOVERY $100 per hour a scientist spends in lab $300 per assay plate $1,000 per team meeting to decide what to do $3,000 per compound that actually gets made $10,000 to see if that compound is orally absorbed in higher-species PK $30,000 to see if a compound cures cancer in mice $100,000 to learn a target is hard to drug from a high-throughput screen $300,000 to make sure a compound is safe in higher species $1,000,000 to find out why it’s not $3,000,000 per day of lost patent life for a blockbuster drug $10,000,000 for a backup candidate because the first didn’t work $100,000,000 to buy a biotech because the backup didn’t either $1,000,000,000 to buy a biotech that had better results in Ph. II $10,000,000,000 lost in market cap because it didn’t work in Ph. III $100,000,000,000 in lifetime revenue missed by being #2 $1,000,000,000,000+ to treat diseases for which a drug isn’t there — Drug discovery is important and incredibly expensive - investing in your team isn’t. Scientists with access to more knowledge and information make better decisions, better compounds, and just move faster. I founded Drug Hunter to empower drug discovery scientists to solve your greatest scientific challenges and design the right studies with inspiration from across the industry. Drug Hunter can save the average Drug Hunter member 150 hours per year. What could you do with 150 hours? DM me to learn more about full access to Drug Hunter.

🚀 New CRBN Constructs to Advance Targeted Protein Degradation and Drug Discovery 🚀 In the fast-evolving field of #TargetedProteinDegradation (TPD), two newly engineered Cereblon (CRBN) constructs — CRBN_ΔHBD and CRBNmidi — are set to transform drug discovery! 🔬 Why does this matter? Existing CRBN tools had limitations that hindered progress: Minimal TBD Construct: Missing a critical region for ligand/substrate binding, limiting its use in ternary complex studies. Full-Length CRBN:DDB1 Complex: Challenging production and crystallisation. 💡 The Game-Changers Both CRBN_ΔHBD and CRBNmidi have been engineered to overcome these hurdles, enhancing our ability to study CRBN and accelerate drug development. ✅ CRBN_ΔHBD: High-expression in E. coli — Easily accessible for large-scale screening. Validated Activity — Efficient formation of binary and ternary complexes, enabling screening for novel CRBN-binding molecules. ✅ CRBNmidi: Crystallisation — Stable expression in E. coli and high-resolution crystal structures of CRBN's binary/ternary complexes Targeted Design — Unlocks new opportunities for structure-based drug design, guiding the development of next-gen CRBN-based therapeutics. 🌟 Why it’s important These improved constructs will be useful for: High-Throughput Screening: Discover new CRBN-binding molecules to develop molecular glues and PROTACs. Structure-Based Drug Design: Gain detailed insights into protein-ligand interactions to improve compound affinity, selectivity, and degradation. These innovations are a step forward in advancing CRBN-based drug discovery and developing cutting-edge therapies for various diseases! 🔗 References & Read More CRBN_ΔHBD: An engineered cereblon optimized for high throughput screening and molecular glue discovery – Cell Chem Biol, 2024 https://lnkd.in/ghYUdH5w CRBNmidi: Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders – Nature Communications, 2024 https://lnkd.in/gX3hsh5A #TPD #DrugDiscovery #Cereblon #PROTACs #MolecularGlues #ProteinDegradation  

🎯 Start Your Day at the Antibody Therapeutics Xchange with Rachel Fong! 🎯 We're excited to kick off the Antibody Therapeutics Xchange - Maryland 2024 with an insightful Opening Address & Keynote Presentation by Rachel Fong, Director of Strategic Partnerships at Integral Molecular. 🌟 ✨ REGISTER NOW and get your Complimentary Pass! https://lnkd.in/eqvCJ5MG 📅 Date: Monday, 28 October 2024 ⏰ Time: 08:30 AM - 09:00 AM 📍 Location: Marriott College Park, Maryland 💡 What to Expect: 🔬 Learn how cell-based protein arrays like the Membrane Proteome Array (MPA) are transforming antibody specificity testing. ⚙️ Understand the impact of off-target binding and how it contributes to drug attrition and patient risks. 🧪 Rachel Fong with over 10 years at Integral Molecular, has been a key player in launching the MPA platform and managing high-impact collaborations. As a co-author of over a dozen publications, she brings an expert perspective on guiding projects from concept to success. Don't miss this chance to dive deep into cutting-edge solutions that are shaping the future of antibody-based therapies! 🌍🔗 💊Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. #AntibodyTherapeutics #Biotech #Pharma #DrugDevelopment #AntibodyEngineering #Polyspecificity #IntegralMolecular #MembraneProteomeArray #AntibodySpecificity #TherapeuticInnovation #PharmaceuticalResearch #Biopharma #AntibodyDiscovery #MPATechnology #BiotechnologyEvent #TherapeuticDevelopment #ClinicalResearch #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass